Mirena (Levonorgestrel)

Levonorgestrel released from the intrauterine system acts locally on the endometrium and cervical mucus. It thickens cervical mucus to impede sperm entry, suppresses endometrial proliferation, and reduces tubal motility, creating an environment that prevents fertilisation and implantation.

The dose of levonorgestrel in Mirena is fixed at 52 mg within the intrauterine system and is released at approximately 20 µg per day. The prescribing clinician determines the appropriate use and duration; patients do not adjust the dose themselves.

Mirena is not intended for use during pregnancy; it must be removed if pregnancy occurs. For breastfeeding women, the device may be left in place, but clinicians evaluate individual risk‑benefit, as levonorgestrel exposure through breast milk is low. Consultation with a healthcare professional is essential.

To order Mirena, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with combined oral contraceptives, Mirena offers a once‑in‑a‑lifetime insertion lasting up to five years, eliminating daily adherence. Unlike copper IUDs, it releases levonorgestrel, which can reduce menstrual bleeding. Its efficacy is comparable to other long‑acting reversible contraceptives but provides additional therapeutic benefit for heavy bleeding.

Mirena should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperatures. Do not attempt to open or manipulate the system before insertion by a qualified healthcare professional.

Mirena is inserted by a trained clinician into the uterine cavity using a specialized applicator. The procedure is performed in a clinical setting under aseptic conditions, typically after cervical preparation. Once placed, the device remains in situ for up to five years, after which it can be removed or replaced.

Serious but rare risks include uterine perforation during insertion, device expulsion, pelvic infection, and ectopic pregnancy if conception occurs after expulsion. Women should seek immediate medical attention for severe abdominal pain, abnormal bleeding, fever or signs of infection following insertion.

Mirena is contraindicated in women with current pregnancy, active pelvic infection, unexplained vaginal bleeding, known or suspected uterine or cervical cancer, uterine anomalies that impede device placement, and those with hypersensitivity to levonorgestrel or any component of the system. A healthcare professional must assess suitability before insertion.